The 7,111-patient trial that was presented Tuesday at the American College of Rheumatology's annual meeting in San Antonio, and is part of the Merck's application for approval.
Many analysts and doctors believed Arcoxia would only be approved after that study is completed and it demonstrates the drug doesn't increase the risk of heart attacks and strokes.
Merck is scheduled to finish a 23,500 patient study that was designed to study cardiovascular safety in early 2006.
Merck shares were up 36 cents to $31.26 in morning trading on the New York Stock Exchange.
